CAR-T Targeting of Mutant Calreticulin Establishes a Potentially Curative Stem Cell-Directed Therapy for Myeloproliferative Neoplasms
Therapies that eradicate cancer stem cells enable cure, but their feasibility is unknown. We establish an approach to potentially cure MPNs by proving mutant calreticulin to be a MPN stem cell marker that can be targeted by CAR-T cells to selectively wipe out disease in preclinical models of human MPNs.
Authors
- Manuel Baca (ORCID: https://orcid.org/0000-0002-9867-4200)
- Irina V. Lebedeva (ORCID: https://orcid.org/0000-0002-1693-9392)
- Olivia Vergnolle
- Urko del Castillo (ORCID: https://orcid.org/0000-0002-4170-1749)
- Clarisse Kayembe
- A. J. Taylor
- Joseph Michael Scandura (ORCID: https://orcid.org/0000-0002-9525-143X)
- Pouneh Kermani
- Paul Balderes
- Maria Mia Yabut
- Elisabeth K. Nyakatura
- Nassima Messali
- Giovanni Medico
- Daniel Choi
- Giorgio Inghirami
- Franco Castillo Tokumori
Institutions
- Cornell University (US)
- Tri-Institutional Therapeutics Discovery Institute (US)
- Weill Cornell Medicine (US)
Publication Details
- Journal
- bioRxiv (Cold Spring Harbor Laboratory)
- Published
- 2026-02-11
- DOI
- https://doi.org/10.64898/2026.02.09.704856
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00